SLNSW-Safety, activity, and pharmacokinetics of camreli...-TN_cdi_doaj_primary_oai_doaj_org_article_f21c870021a84320a8dfb351e754c7dc

Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study

Full title: Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study

Author/creator: Zhou, Li, Wu, Xiaowen, Chi, Zhihong, Si, Lu, Sheng, Xinan, Kong, Yan, Mao, Lili, Lian, Bin, Tang, Bixia, Yan, Xieqiao, Wang, Xuan, Bai, Xue, Li, Siming, Wei, Xiaoting, Li, Juan, Yang, Qing, Guo, Jun, Cui, Chuanliang.

Call Numbers:

Record Identifier: TN_cdi_doaj_primary_oai_doaj_org_article_f21c870021a84320a8dfb351e754c7dc

Language: English

Formats: Articles

Publishers: England: BioMed Central Ltd

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f21c870021a84320a8dfb351e754c7dc

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study

    Record identifier

    TN_cdi_doaj_primary_oai_doaj_org_article_f21c870021a84320a8dfb351e754c7dc

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f21c870021a84320a8dfb351e754c7dc

    Share

    Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f21c870021a84320a8dfb351e754c7dc

    Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study

    Full title

    Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study

    Author / Creator

    Zhou, Li ; Wu, Xiaowen ; Chi, Zhihong ; Si, Lu ; Sheng, Xinan ; Kong, Yan ; Mao, Lili ; Lian, Bin ; Tang, Bixia ; Yan, Xieqiao ; Wang, Xuan ; Bai, Xue ; Li, Siming ; Wei, Xiaoting ; Li, Juan ; Yang, Qing ; Guo, Jun ; Cui, Chuanliang

    Publisher

    England: BioMed Central Ltd

    Journal title

    BMC cancer, 2022, Vol.22 (1), p.565-565

    Record Identifier

    TN_cdi_doaj_primary_oai_doaj_org_article_f21c870021a84320a8dfb351e754c7dc

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Advanced melanoma Analysis Anti-PD-1 antibody Antitumor agents Apoptosis Camrelizumab Cancer therapies Care and treatment Cell death Committees Cytotoxicity Diagnosis Disease control Dosage and administration Drug dosages Drug therapy Fever Health aspects Hyperthyroidism Hypothyroidism Immunoglobulin G Immunotherapy Ipilimumab Liver Medical research Medical treatment Medicine, Experimental Melanoma Metastases Metastasis Monoclonal antibodies Patient outcomes Patients PD-1 protein Pharmacodynamics Pharmacokinetics Response rates Risk factors Safety Safety and security measures Software Statistical analysis Thyroid hormones Triglycerides Tumors Vitiligo γ-Glutamyltransferase

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_doaj_primary_oai_doaj_org_article_f21c870021a84320a8dfb351e754c7dc

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f21c870021a84320a8dfb351e754c7dc

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections